| Autor: |
Chen D; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA., Van der Ent MA; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA., Lartey NL; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA., King PD; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. |
| Abstrakt: |
Ephrin receptors constitute a large family of receptor tyrosine kinases in mammals that through interaction with cell surface-anchored ephrin ligands regulate multiple different cellular responses in numerous cell types and tissues. In the cardiovascular system, studies performed in vitro and in vivo have pointed to a critical role for Ephrin receptor B4 (EPHB4) as a regulator of blood and lymphatic vascular development and function. However, in this role, EPHB4 appears to act not as a classical growth factor receptor but instead functions to dampen the activation of the Ras-mitogen activated protein signaling (MAPK) pathway induced by other growth factor receptors in endothelial cells (EC). To inhibit the Ras-MAPK pathway, EPHB4 interacts functionally with Ras p21 protein activator 1 (RASA1) also known as p120 Ras GTPase-activating protein. Here, we review the evidence for an inhibitory role for an EPHB4-RASA1 interface in EC. We further discuss the mechanisms by which loss of EPHB4-RASA1 signaling in EC leads to blood and lymphatic vascular abnormalities in mice and the implications of these findings for an understanding of the pathogenesis of vascular anomalies in humans caused by mutations in EPHB4 and RASA1 genes. Last, we provide insights into possible means of drug therapy for EPHB4- and RASA1-related vascular anomalies. |
